Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress.
Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, Kalmbach S, Kreienkamp N, Franke M, Wimmers F, Schuhknecht L, Rosenwald A, Zampieri M, Ott G, Lenz G, Schulze-Osthoff K, Hailfinger S. Gomez Solsona B, et al. Among authors: ott g. Blood Adv. 2023 Dec 26;7(24):7433-7444. doi: 10.1182/bloodadvances.2023010964. Blood Adv. 2023. PMID: 37934892 Free PMC article.
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
Thieblemont C, Altmann B, Frontzek F, Renaud L, Chartier L, Ketterer N, Récher C, Poeschel V, Fitoussi O, Held G, Casasnovas O, Haioun C, Morschhauser F, Glass B, Mounier N, Tilly H, Rosenwald A, Ott G, Lenz G, Molina T, Ziepert M, Schmitz N. Thieblemont C, et al. Among authors: ott g. Blood Adv. 2023 Aug 8;7(15):3968-3977. doi: 10.1182/bloodadvances.2022008888. Blood Adv. 2023. PMID: 36716220 Free PMC article. Clinical Trial.
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, Ilieva K, Landgraf K, Mangelberger-Eberl D, Yousefi K, Berning P, Kurz KS, Ott G, Klener P, Khandanpour C, Horna P, Schanzer J, Steidl S, Endell J, Heitmüller C, Lenz G. Patra-Kneuer M, et al. Among authors: ott g. Front Immunol. 2023 Jul 31;14:1220558. doi: 10.3389/fimmu.2023.1220558. eCollection 2023. Front Immunol. 2023. PMID: 37600821 Free PMC article.
An aggressive mediastinal EBV-associated large B cell lymphoma.
Kurz KS, Noerenberg D, Schaich M, Bethge W, Horn H, Staiger AM, Fend F, Damm F, Ott G. Kurz KS, et al. Among authors: ott g. Histopathology. 2024 Apr 2. doi: 10.1111/his.15183. Online ahead of print. Histopathology. 2024. PMID: 38566333 No abstract available.
A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.
Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, Hummel M, Jaffe ES, Küppers R, Lefebvre C, Lisfeld J, Löffler M, Macleod RA, Nagel I, Oschlies I, Rosolowski M, Russell RB, Rymkiewicz G, Schindler D, Schlesner M, Scholtysik R, Schwaenen C, Spang R, Szczepanowski M, Trümper L, Vater I, Wessendorf S, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphoma Network Project; Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group. Salaverria I, et al. Blood. 2014 Feb 20;123(8):1187-98. doi: 10.1182/blood-2013-06-507996. Epub 2014 Jan 7. Blood. 2014. PMID: 24398325 Free PMC article.
What Is a Sarcoma 'Specialist Center'? Multidisciplinary Research Finds an Answer.
Wilson R, Reinke D, van Oortmerssen G, Gonzato O, Ott G, Raut CP, Guadagnolo BA, Haas RLM, Trent J, Jones R, Pretorius L, Felser B, Basson M, Schuster K, Kasper B. Wilson R, et al. Among authors: ott g. Cancers (Basel). 2024 May 13;16(10):1857. doi: 10.3390/cancers16101857. Cancers (Basel). 2024. PMID: 38791936 Free PMC article.
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
Hilton LK, Collinge BJ, Ben-Neriah S, Alduaij W, Shaalan H, Weng A, Cruz M, Slack GW, Farinha P, Miyata-Takata T, Boyle M, Meissner B, Cook JR, Ondrejka SL, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami GG, Jaffe ES, Weisenburger DD, Chan WC, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Sehn LH, Savage KJ, Mungall AJ, Feldman AL, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW. Hilton LK, et al. Among authors: ott g. Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251. Online ahead of print. Blood. 2024. PMID: 38701426
What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?
Attygalle AD, Chan JKC, Coupland SE, Du MQ, Ferry JA, de Jong D, Gratzinger D, Lim MS, Nicolae A, Ott G, Rosenwald A, Schuh A, Siebert R; WHO 5th Edition Classification Project. Attygalle AD, et al. Among authors: ott g. J Hematop. 2024 Jun;17(2):71-89. doi: 10.1007/s12308-024-00585-8. Epub 2024 Apr 29. J Hematop. 2024. PMID: 38683440 Review.
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.
Kalla C, Ott G, Finotello F, Niewola-Staszkowska K, Conza GD, Lahn M, van der Veen L, Schüler J, Falkenstern-Ge R, Kopecka J, Riganti C. Kalla C, et al. Among authors: ott g. Transl Oncol. 2024 May;43:101857. doi: 10.1016/j.tranon.2023.101857. Epub 2024 Feb 27. Transl Oncol. 2024. PMID: 38412661 Free PMC article.
784 results